Previous 10 | Next 10 |
Genmab A/S (GMAB) Q3 2020 Earnings Conference Call November 4, 2020 12:00 ET Company Participants Jan van de Winkel - President and Chief Executive Officer Anthony Pagano - Chief Financial Officer Judith Klimovsky - Chief Development Officer Anthony Mancini - Chief Operating Officer Conferenc...
Genmab A/S (GMAB): Q3 GAAP EPS of DKK8.04 beats by $DKK1.88.Revenue of DKK1.72B (+65.4% Y/Y) beats by DKK260M.Press Release For further details see: Genmab A/S EPS beats by DKK1.88, beats on revenue
The first participant has been dosed in an additional arm of a Phase 1b clinical trial evaluating ADC Therapeutics' (ADCT) antibody-drug conjugate camidanlumab tesirine (Cami) (formerly ADCT-301), combined with Merck's (MRK) Keytruda (pembrolizumab), in patients with advanced solid ...
Genmab A/S (GMAB) and ADC Therapeutics SA (ADCT) have amended their 2013 collaboration agreement related to continued development and commercialization of antibody-drug conjugate ((ADC)) camidanlumab tesirine (Cami).The revised contract eliminates the defined divestment process and allows ADC...
Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could dominate the industry based on their disruptive technology, unique offerings and tremendo...
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300. Genmab reports positive data from Phase 2 CASSIOPEIA study. For further details see: NantKwest COVID-19 Candidate, And Other ...
Genmab A/S (GMAB) announces positive results from the second part of a Phase 3 clinical trial, CASSIOPEIA, evaluating daratumumab as maintenance treatment versus no treatment in newly diagnosed multiple myeloma ((MM)) patients who are eligible for autologous stem cell transplantation.Part 2, ...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...
Amgen (AMGN), Genmab A/S (GMAB), Seattle Genetics (SGEN), and Alexion Pharmaceuticals (ALXN) are leading biotech companies engaged in developing cancer drugs. As the number of cancer patients rises with each passing day, these stocks should continue to move higher. Biotech stocks are amon...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 01:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...